国际生殖健康/计划生育杂志 ›› 2025, Vol. 44 ›› Issue (3): 201-203.doi: 10.12280/gjszjk.20240637

• 病例报告 • 上一篇    下一篇

CAMK2A基因变异致常染色体显性智力发育障碍53型一例

郝重阳, 刘万超, 金紫荷, 刘丽颖, 王美玲, 王荣()   

  1. 067000 承德医学院(郝重阳,刘万超,金紫荷);沧州市人民医院儿科(郝重阳,刘万超,金紫荷,刘丽颖,王美玲,王荣)
  • 收稿日期:2024-12-28 出版日期:2025-05-15 发布日期:2025-06-04
  • 通讯作者: 王荣,E-mail:czhwr@163.com

A Case of Mental Retardation, Autosomal Dominant 53 Related to CAMK2A Gene Variant

HAO Chong-yang, LIU Wan-chao, JIN Zi-he, LIU Li-ying, WANG Mei-ling, WANG Rong()   

  1. Chengde Medical College, Chengde 067000, Hebei Province, China (HAO Chong-yang, LIU Wan-chao, JIN Zi-he); Department of Pediatrics, Cangzhou People′s Hospital, Cangzhou 061000, Hebei Province, China (HAO Chong-yang, LIU Wan-chao, JIN Zi-he, LIU Li-ying, WANG Mei-ling, WANG Rong)
  • Received:2024-12-28 Published:2025-05-15 Online:2025-06-04
  • Contact: WANG Rong, E-mail: czhwr@163.com

摘要:

CAMK2A基因变异可致常染色体显性智力发育障碍53型(mental retardation, autosomal dominant 53,MRD53),临床可表现为癫痫发作、发育迟滞、智力障碍和行为异常,国内外报道较少。报告1例因癫痫发作、行为异常就诊的MRD53患儿,基因测序提示患儿CAMK2A基因c.775C>T(p.Arg259Cys)错义变异,突变位点为5号染色体,外显子11由胞嘧啶(C)变为胸腺嘧啶(T),导致精氨酸变为半胱氨酸[p.R259C(p.Arg259Cys)(NM_001363989)],其父母均未发生变异。该突变是一个新发现的CAMK2A基因突变,可导致MRD53。目前MRD53尚无特效药物治疗,主要为对症支持治疗,临床上此类患儿需要多学科的密切合作,严格把控用药,注重患儿身心健康的培养。另外,需加强临床对该疾病遗传的认识,其治疗和预后仍然是未来研究的重点方向。

关键词: 发育障碍, 癫痫, 智力障碍, 基因, 遗传变异, 常染色体显性智力发育障碍53型

Abstract:

CAMK2A gene variation can cause the mental retardation, autosomal dominant 53 (MRD53), which can be clinically manifested as epilepsy, developmental retardation, intellectual impairment and behavioral abnormalities. There are few reports at home and abroad. We report a case of MRD53 child who was treated for epileptic seizures and behavioral abnormalities. Gene sequencing indicated a missense mutation of the CAMK2A gene c.775C>T(p.Arg259Cys). The mutation site was chromosome 5, and exon 11 changed from cytosine (C) to thymine (T). It caused a change at the amino 259 site of the coded protein from arginine to cysteine [p.R259C(p.Arg259Cys)(NM_001363989)]. Neither of the parents has any mutation. This mutation is a new mutation, which may lead to MRD53. Currently, there is no specific drug treatment for MRD53. The symptomatic supportive treatment is the primary method, including strict control of diet, mood and medication, and paying attention to the cultivation of physical and mental health of children. Further research on the genetics, treatment and prognosis of this disease may be a key direction for future studies.

Key words: Developmental disabilities, Epilepsy, Intellectual disability, Genes, Genetic variation, Mental retardation, autosomal dominant 53